NASDAQ: AKTXAkari Therapeutics PLC Stock
$3.62+0.13 (+3.72%)
Updated Sep 22, 2023
AKTX Price
$3.62
Fair Value Price
$3.83
Market Cap
$26.95M
52 Week Low
$2.81
52 Week High
$13.40
P/E
N/A
P/B
15.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.75M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
6.72
Operating Cash Flow
-$22M
Beta
0.59
Next Earnings
Sep 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A
AKTX Overview
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKTX ($3.62) is undervalued by 5.54% relative to our estimate of its Fair Value price of $3.83 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AKTX ($3.62) is not significantly undervalued (5.54%) relative to our estimate of its Fair Value price of $3.83 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AKTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more AKTX due diligence checks available for Premium users.
Be the first to know about important AKTX news, forecast changes, insider trades & much more!
AKTX News
Valuation
AKTX fair value
Fair Value of AKTX stock based on Discounted Cash Flow (DCF)
Price
$3.62
Fair Value
$3.83
Undervalued by
5.54%
AKTX ($3.62) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AKTX ($3.62) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AKTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
12.89x
Market
14.52x
AKTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.05x
Industry
5.11x
AKTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AKTX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
AKTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$13.8M
Liabilities
$12.0M
Debt to equity
6.72
AKTX's short-term assets ($13.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKTX's short-term assets ($13.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
AKTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKTX vs Biotech Stocks
Akari Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.